Title: Age comparative study of chronic sub dural hematoma and its outcome :- A retrospective study
Author(s): Dr. Nilesh Potdar1,Dr. S Suresh Kumar2,Dr. Bhavadasan K3
1(M.S.,PG 3rd yr) Department of Neurosurgery,Amala Institute of Medical Sciences, Amalanagar,
Thrissur, Kerala – 680555
2M.S., M.Ch., DNB (CORRESPONDING AUTHOR) ,ADDRESS : Senior Consultant Neurosurgeon, Associate Professor & Unit Chief ,Department of Neurosurgery, Amala Institute of Medical Sciences, Amalanagar, Thrissur, Kerala - 680555
3(M.Ch.HOD AND PROFESSOR) ,ADDRESS : Senior Consultant Neurosurgeon, Professor & Unit Chief , Department of Neurosurgery, Amala Institute of Medical Sciences, Amalanagar, Thrissur, Kerala - 680555
Objective:-Chronic subdural hematoma (CSDH) is a common disease among the elderly and with increasing incidence in the younger population, we have chosen to focus on CSDH in the different age groups so we can differentiate between presentation and radiological finding and etiological factor in each groups.
Methods :-We conducted a retrospective review of 196 patients undergoing surgery for CSDH over a period of five years (2011–2016). Risk factors such as age, head trauma, anticoagulant and/or antiplatelet agent therapy and co-morbidity were investigated along with gender, laterality, surgical method and recurrence. We divided our patient in four groups according to age. Results:-Seventy-two percent of the patients were male and the mean age was 70% years (range 2–92 years). Headache was the most common symptom of presentation (63%). Maximum numbers of patients were found in the age group 61-75 years 74(38%) . Association of head trauma in each group is the main etiological factor. CSDH is associated with brain atrophy in elderly and older age group.
Conclusion :-Recurrence and bilateral disease are more common in old age group .Trauma to head is most common etiological factor in each age group .brain atrophy is etiological factor associated with old age group . Antiplatelet or anticoagulant therapy is associated as risk factor for the CSDH in all age groups.The use of antiplatelet or anticoagulant should be restricted to truly indicated patients.